Posted on

ROVI is once again running for inclusion

Ready…

Steady…

GO!

On Sunday 7 November we once again put on our running shoes for a good cause: the inclusion of people with motor disabilities. Our ROVI colleagues ran together in the Madrid También Solidario race, organised by the También Foundation, which this year celebrated its tenth edition.

This event brought back good feelings and, above all, the pleasure of being reunited after the pandemic. Our colleagues were able to run 1, 5 or 10 km and wanted to share their experience with us.
Don’t miss the video!

Posted on

Update 91. COVID-19: Use of microwave ovens

In order to help employees adaptation to the increased presence at headquarters, the use of microwave ovens will be permitted for heating food to be taken at the workstation.

As far as possible, we ask to avoid the crowds in the canteen when microwaves are to be used. In addition, as with other commonly used devices, employees should make use of the hydro-alcoholic gel in the canteens before use.

The microwaves can be used from Monday onwards.

Obligatory use of masks

We insist on the obligatory use of the mask during the whole working day. It can only be removed at the workplace when eating or drinking.

Also, we recommend the employees to follow the same instructions when they go outside during the working day.

Lifts

We remind you that the use of lifts is still restricted to one person per trip.
This committee has been observing systematic non-compliance with these last two rules.

We would like to remind you that any behaviour that does not comply with the COVID-19 prevention measures established at ROVI may be subject to sanctions.

Posted on

ROVI celebrated its Capital Markets Day

ROVI held its Capital Markets Day where it explained to investors and analysts its strategic vision on the evolution of the business, its R&D plans and the main financial figures. It highlights the operating income forecast for this year, which stands at between 588 and 609 million euros, which would bring forward the achievement of the 2023 target by two years.

Another of the main developments announced at this meeting was the resumption of the regulatory process for Risperidone ISM in Europe, following the successful repetition of the clinical bioavailability study and the submission of the information to the European Medicines Agency.

In front of approximately 60 investors or representatives of investment groups, Juan López-Belmonte, President and CEO of ROVI, reviewed what will be its growth drivers for 2022:

  • Low molecular weight heparins, bemiparin and the biosimilar enoxaparin.
  • Distribution licensing agreements, such as Neparvis® and Volutsa®.
  • The existing portfolio of speciality pharmaceuticals
  • The agreement with Moderna for the manufacture of the COVID-19 vaccine.
  • New contracts in the area of third-party manufacturing.

This will be accompanied by a high level of investment in the international arena, with the aim of reaching a presence in 120 countries in the coming years and a sales team specialising in the psychiatric area in Europe, as well as the consolidation of the new plant for the active ingredient Low Molecular Weight Heparins in Granada and the new Moderna manufacturing lines.

Posted on

ROVI increases net profit by 111% to almost 100 million euros

ROVI reports operating revenue growth of 53% and doubles its ebitda

  • Operating revenue increased by 53% to 463.5 million euros driven by (i) the strength of the contract manufacturing organization (“CMO”) business, which grew by 187%, and (ii) the specialty pharmaceutical business, where sales rose 18%.
  • Sales of the heparin franchise (Low Molecular Weight Heparins (LMWH) and other heparins) increased by 15% to 181.5 million euros. Sales of the enoxaparin biosimilar increased 17% to 89.9 million euros and sales of Bemiparin increased 13% to 86.3 million euros.
  • EBITDA doubled to 139.5 million euros.
  • Net profit increased by 111% to 98.9 million euros.
  • ROVI’s ESG aspects have been evaluated by Sustainalytics, having obtained an “ESG Risk Rating 2021” of 18.4, which places the company at low risk (between 10 and 20). ROVI has attained the second position out of 432 companies in the sub-industry “pharmaceuticals”. ROVI General Shareholders Meeting approved the payment of a gross dividend of 0.3812 euros per share on 2020 earnings (+118%). This dividend was paid on July, 7th.
Posted on

We started vaccination campaign

Next week we will start with the vaccination campaign in ROVI. We will install mobile units in the headquarters, and you will be assigned appointments and times to go in an orderly manner, respecting the safety distances and capacity control.

The Department of Safety and Environment will publish a list in each workplace in which the day and time of vaccination assigned to each employee can be consulted. IMPORTANT: to comply with data protection regulations, this list is encrypted, so the EMPLOYEE NUMBER and the appointment will appear.

If you do not know your employee number, you can easily consult it in ROVIROCKS, following these steps:

You can also see it in TALENTIA, from the “My working data” section.

Sales delegates from Madrid and Granada must go to the ROVI centres to receive the vaccine on the assigned days. For the rest of the members of the commercial network, Quiron will contact them in the coming days to inform them about when and where to receive the vaccine.

The vaccination SHIFTS in the centres are: